News Search Results
Jul 10, 2025, 07:00 ET Corero Network Security Enables Cloud-Native DDoS Orchestration in Akamai Compute
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced that the orchestration plane of its flagship
More news about: Corero Network Security
Jul 09, 2025, 16:30 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for June 2025
YORK, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $88.9 billion as of June 30, 2025,
More news about: Cohen & Steers, Inc.
Jul 09, 2025, 16:25 ET Cohen & Steers, Inc. to Release Second Quarter 2025 Results on July 17, 2025
YORK, July 9, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release second quarter 2025 results after the market closes on Thursday, July 17, 2025. The
More news about: Cohen & Steers, Inc.
Jul 09, 2025, 12:00 ET Zhimeng Biopharma's Next-Generation KCNQ2/3 Potassium Channel Opener Receives Clinical Trial Approval for ALS Phase 2/3 Study
Inc. ("Zhimeng Biopharma"), a clinical-stage biopharmaceutical company dedicated to innovative drug development for liver and central nervous system (CNS) diseases, today announced that its self-discovered next-generation KCNQ2/3 potassium channel opener, CB03-154, has received an approval from the Center
More news about: Shanghai Zhimeng Biopharma, Inc.
Jul 09, 2025, 08:00 ET Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Jul 08, 2025, 23:28 ET 코헨 앤드 스티어스, 한국 기관 비즈니스 총괄에 신윤현 (Andrew Shin) 부사장 임명
https://www.cohenandsteers.com주식 심벌: 뉴욕증권거래소(NYSE): CNS 미래예측진술 본 보도자료 및 코헨 앤드 스티어스가 향후 발표할 수 있는 기타 진술에는 1933년 증권법 제27A조(수정 조항) 및 1934년 증권거래법 제21E조(수정 조항)에 따른 미래예측진술이 포함될 수 있으며, 이러한 진술에는 회사의 운영
More news about: Cohen & Steers, Inc.
Jul 08, 2025, 09:00 ET Sensorium Therapeutics Receives FDA IND Clearance for SNTX-2643, a First-in-Class, Rapid-Acting Anxiolytic
Harvard Medical School professor—as Chief Executive Officer. Dr. Hooker is a world-renowned expert in chemical neuroscience, biomarker development, and CNS pharmacology. He has co-founded and advised several biotech companies, including Eikonizo Therapeutics, Delix Therapeutics, and Rocket Science Health.
More news about: Sensorium Therapeutics, Inc
Jul 08, 2025, 03:30 ET Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson's Disease
Neuraxpharm's commitment to realising innovative solutions in CNS care. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders.
More news about: Neuraxpharm
Jul 07, 2025, 14:22 ET Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid
nervous system (CNS) cancers, announced the results of the analytical validation study of the Belay Vantage™ assay for detection of MGMT (Methylation of the O6-methylguanine-DNA methyl-transferase) promoter methylation in cerebrospinal fluid (CSF) for primary and metastatic CNS cancers as
More news about: Belay Diagnostics
Jul 07, 2025, 07:00 ET Cooper University Health Care Selects Corero Network Security to Implement Zero Trust Admission Control
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, today announced that
More news about: Corero Network Security
Jul 03, 2025, 06:07 ET MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
targeting)~30% CAR+ CD8+ T-cell generation from a single low dose in NHPB-cell depletion via in vivo CAR-T in NHPsBBB-crossing delivery in CNS murine modelsWhat's next? MOTE is raising >$40M in Series A funding to support IND-enabling
More news about: MOTE
Jul 02, 2025, 10:00 ET iQure Pharma Appoints Former UCB Chief Medical Officer and Head of Development, Prof. Iris Loew-Friedrich, MD, as Clinical and R&D Advisor
2025 /PRNewswire/ -- iQure Pharma, a clinical-stage biotech company breaking the cycle of excitotoxicity by restoring glutamate balance to treat CNS disorders, today announced the appointment of Prof. Dr. Iris Loew-Friedrich as Clinical and R&D Advisor.
More news about: iQure Pharma Inc.
Jul 02, 2025, 09:00 ET Headlands Research Enters the Caribbean with Acquisition of CMRCenter
sponsors a turnkey, single-contract gateway to one of the largest Hispanic patient populations under FDA oversight and accelerating enrollment for vaccine, CNS, and specialty studies.
More news about: Headlands Research
Jun 30, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity Financing
Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders, today announced that it has completed the second and final $1 million closing of its previously disclosed
More news about: NLS Pharmaceutics AG
Jun 27, 2025, 07:00 ET Corero Network Security Joins World Wide Technology as Certified Partner to Advance Cyber Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), the distributed denial of service (DDoS) protection specialists, announced it has been named a Certified Partner in the
More news about: Corero Network Security
Jun 26, 2025, 11:44 ET Eternum LLC Acquires Renewal Kit for Travelers™, Launches Goal Time™ -- A Science-Backed Travel Resilience Supplement for All Travelers
travel." Formulated with the guidance of renowned clinical nutritionist Dr. Patti Milligan, PhD, RD, CNS, Goal Time™ is engineered to support the systems most affected by travel: energy, digestion, and immunity. Dr. Milligan invites
More news about: Eternum LLC
Jun 26, 2025, 08:30 ET STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer
discovery of breakthrough small molecule drugs that precisely reprogram cells through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases. STORM's lead product, STC-15, is the first RNA modifying enzyme inhibitor to enter human clinical development. STC-15
More news about: STORM Therapeutics
Jun 26, 2025, 08:03 ET HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Agreement to Acquire Interest in Cohen and Associates, LLC for HOPE's Network of Interventional Psychiatry Clinics
of the premier Interventional Psychiatry clinics in the region. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders, including ketamine, Spravato, Transcranial Magnetic Stimulation ("TMS") as well as medication management. Dr. Cohen is an Interventional
More news about: NRx Pharmaceuticals, Inc.
Jun 25, 2025, 12:29 ET Access Free Educational Videos and Webinars Provided by the Multiple Sclerosis Association of America
Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord. MS damages or destroys the protective covering (known as myelin) surrounding the nerves of the CNS and can potentially injure the nerves as well. This damage causes reduced
More news about: Multiple Sclerosis Association of America
Jun 24, 2025, 17:19 ET Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:18 ET Cohen & Steers Total Return Realty Fund, Inc. (RFI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:10 ET Cohen & Steers Quality Income Realty Fund, Inc. (RQI) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:04 ET Cohen & Steers Closed-End Opportunity Fund, Inc. (FOF) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.comSymbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 17:00 ET Cohen & Steers REIT and Preferred and Income Fund, Inc. (RNP) Notification of Sources of Distribution Under Section 19(a)
https://www.cohenandsteers.com/Symbol: (NYSE: CNS) About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income,
More news about: Cohen & Steers, Inc.
Jun 24, 2025, 09:00 ET Cohen & Steers Appoints Brad Ispass as Head of Enterprise Wealth
YORK, June 24, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of Brad Ispass as Head of Enterprise Wealth, a newly created role that will lead the
More news about: Cohen & Steers, Inc.